The Cooper Companies, Inc. $COO Stock Position Lessened by Forum Financial Management LP

Forum Financial Management LP decreased its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 9.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 4,913 shares of the medical device company’s stock after selling 520 shares during the quarter. Forum Financial Management LP’s holdings in Cooper Companies were worth $350,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of COO. Asset Management One Co. Ltd. grew its stake in shares of Cooper Companies by 15.2% in the first quarter. Asset Management One Co. Ltd. now owns 85,567 shares of the medical device company’s stock worth $7,218,000 after purchasing an additional 11,320 shares in the last quarter. Diversified Trust Co grew its stake in shares of Cooper Companies by 12.5% in the first quarter. Diversified Trust Co now owns 10,229 shares of the medical device company’s stock worth $863,000 after purchasing an additional 1,135 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Cooper Companies by 15.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,189 shares of the medical device company’s stock worth $2,194,000 after purchasing an additional 3,440 shares in the last quarter. KBC Group NV lifted its holdings in shares of Cooper Companies by 1.2% in the first quarter. KBC Group NV now owns 251,968 shares of the medical device company’s stock valued at $21,253,000 after buying an additional 3,045 shares during the period. Finally, Amalgamated Bank lifted its holdings in shares of Cooper Companies by 1.6% in the first quarter. Amalgamated Bank now owns 38,686 shares of the medical device company’s stock valued at $3,263,000 after buying an additional 597 shares during the period. Institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. BNP Paribas upgraded Cooper Companies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 22nd. Barclays assumed coverage on Cooper Companies in a report on Monday, October 13th. They issued an “overweight” rating and a $85.00 price objective for the company. Mizuho cut their price objective on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating for the company in a report on Wednesday, July 16th. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Finally, The Goldman Sachs Group set a $64.00 price objective on Cooper Companies and gave the company a “sell” rating in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cooper Companies has an average rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Trading Down 1.4%

Shares of NASDAQ COO opened at $73.51 on Friday. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $108.32. The company has a market cap of $14.61 billion, a price-to-earnings ratio of 36.21, a P/E/G ratio of 1.93 and a beta of 1.02. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The business has a fifty day simple moving average of $69.67 and a 200-day simple moving average of $73.25.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business posted $0.96 earnings per share. Cooper Companies’s revenue was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, COO Daniel G. Mcbride acquired 3,000 shares of Cooper Companies stock in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average cost of $65.04 per share, with a total value of $195,120.00. Following the purchase, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. The trade was a 4.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction that occurred on Monday, September 29th. The stock was acquired at an average cost of $68.39 per share, with a total value of $136,780.00. Following the completion of the purchase, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This represents a 52.95% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 17,975 shares of company stock valued at $1,216,346 over the last 90 days. 1.98% of the stock is owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.